Capricor Therapeutics and CureDuchenne to Host Webinar on January 21, 2015 at 3:00 p.m. ET

Presentation to Discuss Capricor's Duchenne Muscular Dystrophy Clinical Program

LOS ANGELES, Jan. 21, 2015 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (OTCBB:CAPR), a biotechnology company focused on developing novel therapeutics for the treatment of cardiovascular diseases and CureDuchenne, a national nonprofit organization dedicated to finding a cure for Duchenne muscular dystrophy, invite participants to join a webinar on Wednesday, January 21, 2015 at 3:00 p.m. ET/12:00 p.m. PT.

CureDuchenne logo


Dr. Linda Marbán, Chief Executive Officer of Capricor Therapeutics, Eduardo Marbán, M.D., Ph.D., Capricor's Scientific Advisory Board Chairman and the Director of the Cedars-Sinai Heart Institute, and Debra Miller, Co-Founder and Chief Executive Officer of CureDuchenne will discuss research to treat heart disease associated with Duchenne muscular dystrophy and their plans to advance clinical research for the treatment of Duchenne. Heart failure is the leading cause of death in patients with Duchenne. Positive pre-clinical data for cardiosphere-derived cells (CDCs) on Duchenne muscular dystrophy cardiomyopathy was recently presented at the Annual American Heart Association Scientific Sessions. CureDuchenne has invested in Capricor to support the development of its planned clinical program for Duchenne. The discussants will follow the presentation with a question and answer session.

To join the webinar please call (844) 337-8088 and enter conference ID number 65477372. To view the presentation, you may register online at: https://cc.readytalk.com/cc/s/registrations/new?cid=1s7482dtk3s.

About Capricor Therapeutics

Capricor Therapeutics, Inc. (CAPR), a publicly traded biotechnology company, is focused on the development of novel therapeutics to prevent and treat heart disease. The Company has two leading product candidates: CAP-1002 and Cenderitide. The Company was formed through the November 2013 merger between Capricor, Inc., a privately held company whose mission is to improve the treatment of heart disease by commercializing cardiac stem cell therapies for patients, and Nile Therapeutics, Inc., a clinical-stage biopharmaceutical company developing innovative products for the treatment of cardiovascular diseases. For additional information visit www.capricor.com.

About CureDuchenne Ventures and CureDuchenne

CureDuchenne Ventures LLC collaborates with pharmaceutical and biotechnology companies to facilitate the development of drugs to treat Duchenne muscular dystrophy. CureDuchenne Ventures LLC was formed by CureDuchenne, a national nonprofit that has a successful track record of supporting research and raising awareness of the disease.

CureDuchenne is a national nonprofit organization located in Newport Beach, California, dedicated to finding a cure for Duchenne, the most common and most lethal form of muscular dystrophy. As the leading genetic killer of young boys, Duchenne affects more than 300,000 boys worldwide. CureDuchenne has garnered international attention for its efforts to raise funds and awareness for Duchenne. With the help of CureDuchenne's distinguished international panel of Scientific Advisors, funds raised by CureDuchenne support the most promising research aimed at treating and curing Duchenne. To date, seven CureDuchenne research projects have made their way into human clinical trials – a unique accomplishment as few health-related nonprofits have been successful in being a catalyst for human clinical trials.

Cautionary Note Regarding Forward-Looking Statements

Statements in this press release regarding the efficacy, safety, and intended utilization of Capricor's product candidates; the conduct, size, timing and results of discovery efforts and clinical trials; plans regarding regulatory filings, future research and clinical trials; plans regarding current and future collaborative activities and the ownership of commercial rights; future royalty streams, and any other statements about Capricor's management team's future expectations, beliefs, goals, plans or prospects constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "believes," "plans," "could," "anticipates," "expects," "estimates," "should," "target," "will," "would" and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements. More information about these and other risks that may impact our business are set forth in our Form 10-K for the year ended December 31, 2013, as filed with the Securities and Exchange Commission on March 31, 2014, in our Amendment No. 1 to Registration Statement on Form S-1, as filed with the Securities and Exchange Commission on May 23, 2014, and in our Form 10-Q for the quarter ended September 30, 2014, as filed with the Securities and Exchange Commission on November 14, 2014. All forward-looking statements in this press release are based on information available to us as of the date hereof, and we assume no obligation to update these forward-looking statements.

CONTACT: For more information, please contact:

         Capricor Therapeutics, Inc.
         AJ Bergmann, Vice President of Finance
         +1-310-358-3200
         abergmann@capricor.com

         ProActive Capital Group
         Investor Contact:
         Kirin Smith, COO
         646-863-6519
         ksmith@ProActiveCapital.com

         Media Contact:
         Sean Leous, Managing Director of PR
         646-863-8998
         sleous@pcgadvisory.com

         www.ProActiveCapital.com

Capricor Therapeutics logo

Source: Capricor Therapeutics